Acute Myeloid Leukemia, Aplastic Anemia, Autoimmune Hemolytic Anemia, AIHA, Bleeding Disorder, Blood Disease Infection, Bone Marrow Transplantation, Essential Thrombocythemia, ET, Hemophilia, Hemophilia A, Hemophilia B, Large Granular Lymphocyte Leukemia, LGLL, Leukemia, Lymphoma, MDS, Multiple Myeloma, Myelodysplastic Syndrome, Paroxysmal Nocturnal Hemoglobinuria, PNH
Conditions
Brief summary
Background Hematological diseases are disorders of the blood and hematopoietic organs. The current hematological cohorts are mostly based on single-center or multi-center cases, or cohorts with limited sample size in China. There is a lack of comprehensive and large-scale prospective cohort studies in hematology. The purpose of this study is to analyze the incidence and risk factors of major blood diseases, the treatment methods, prognosis and medical expenses of these patients in China. Method The study will include patients diagnosed with acute myeloid leukemia, multiple myeloma, hemophilia, aplastic anemia, leukemia, myelodysplastic syndrome, lymphoma, bleeding disorders, autoimmune hemolytic anemia, large granular lymphocyte leukemia, essential thrombocythemia, blood infection or received bone marrow transplantation in the investigating hospitals from January 1, 2020, and collect basic information, diagnostic and treatment information, prognosis information, as well as medical expense information from medical records. In its current form, the NICHE registry incorporates historical data (collected from 2000) and is systematically collecting prospective data in two phases with broadening reach, and prospectively follow-up to collect the prognosis information.
Interventions
None listed
Sponsors
Institute of Hematology & Blood Diseases Hospital, China
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Patients who were diagnosed with acute myeloid leukemia, multiple myeloma, hemophilia, aplastic anemia, leukemia, myelodysplastic syndrome, lymphoma, bleeding disorders or received bone marrow transplantation in the investigating hospitals from January 1, 2020.
Exclusion criteria
* Long-term follow-up information for patients is not available for any reason, such as not being available or having a serious concomitant disease. * Alcohol and drug addictions affect their ability to comply with study requirements. * According to the investigator, there are conditions that may endanger the patient's safety or affect his/her compliance.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence and distribution | 5 years | To describe the incidence and population characteristics of hematological diseases in China, such as: leukemia, multiple myeloma, hemophilia, aplastic anemia, myelodysplastic syndrome, lymphoma, bleeding disorders, blood disease infection, et al., and analyze the risk factors associated with these diseases. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Therapeutic evaluation | 5 years | To analyze the therapeutic efficacy and long-term prognosis of patients with hematological diseases, such as: leukemia, multiple myeloma, hemophilia, aplastic anemia, myelodysplastic syndrome, lymphoma, bleeding disorders, blood disease infection, et al. |
| Health economic evaluation | 5 years | To conduct health economic evaluation on patients with hematological diseases, such as: leukemia, multiple myeloma, hemophilia, aplastic anemia, myelodysplastic syndrome, lymphoma, bleeding disorders, blood disease infection, et al. |
Countries
China
Contacts
CONTACTZhen Song, MD
Outcome results
None listed